A Study to Investigate Efficacy and Safety of a TCA108 in Participants ≥18 Years With Uncontrolled Hypertension

NCT07030101 · Status: NOT_YET_RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 400

Last updated 2025-11-24

No results posted yet for this study

Summary

The purpose of this study if to evaluate the efficacy and safety of TCA108 in the treatment of hypertension.

Conditions

Interventions

DRUG

TCA108

TCA108

DRUG

Bramicar HCT

Bramicar HCT

DRUG

Micardis Anlo

Micardis Anlo

Sponsors & Collaborators

  • EMS

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-11-30
Primary Completion
2029-05-31
Completion
2029-11-30

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07030101 on ClinicalTrials.gov